Agilon Health Inc (NYSE: AGL)’s stock price has gone decline by -10.25 in comparison to its previous close of 3.22, however, the company has experienced a -30.53% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-05-06 that agilon health, inc. (NYSE:AGL ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Evan Smith – Senior Vice President of Investor Relations Steve Sell – Chief Executive Officer Jeff Schwaneke – Chief Financial Officer Conference Call Participants Stephen Baxter – Wells Fargo Elizabeth Anderson – Evercore ISI Jailendra Singh – Truist Securities Justin Lake – Wolfe Research Amir Farahani – Bernstein Lisa Gill – JPMorgan Ryan Langston – TD Cowen Joanna Gajuk – Bank of America Ryan Daniels – William Blair Michael Ha – Baird Matthew Shea – Needham Daniel Grosslight – Citi Jenny Shen – BTIG George Hill – Deutsche Bank Whit Mayo – Leerink Partners Thomas Walsh – Barclays Operator Hello, everybody, and welcome to the agilon health First Quarter 2025 Earnings Conference Call.
Is It Worth Investing in Agilon Health Inc (NYSE: AGL) Right Now?
Additionally, the 36-month beta value for AGL is 0.37. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 15 rating it as “hold,” and 0 rating it as “sell.”
The public float for AGL is 302.78M and currently, short sellers hold a 7.25% ratio of that float. The average trading volume of AGL on May 12, 2025 was 6.25M shares.
AGL’s Market Performance
AGL’s stock has seen a -30.53% decrease for the week, with a -44.21% drop in the past month and a -13.21% fall in the past quarter. The volatility ratio for the week is 16.42%, and the volatility levels for the past 30 days are at 11.76% for Agilon Health Inc The simple moving average for the past 20 days is -31.33% for AGL’s stock, with a -18.81% simple moving average for the past 200 days.
Analysts’ Opinion of AGL
Many brokerage firms have already submitted their reports for AGL stocks, with Citigroup repeating the rating for AGL by listing it as a “Buy.” The predicted price for AGL in the upcoming period, according to Citigroup is $5 based on the research report published on April 25, 2025 of the current year 2025.
Bernstein, on the other hand, stated in their research note that they expect to see AGL reach a price target of $8.50. The rating they have provided for AGL stocks is “Outperform” according to the report published on April 08th, 2025.
Citigroup gave a rating of “Neutral” to AGL, setting the target price at $2.25 in the report published on January 10th of the current year.
AGL Trading at -30.69% from the 50-Day Moving Average
After a stumble in the market that brought AGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.61% of loss for the given period.
Volatility was left at 11.76%, however, over the last 30 days, the volatility rate increased by 16.42%, as shares sank -47.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.73% lower at present.
During the last 5 trading sessions, AGL fell by -30.53%, which changed the moving average for the period of 200-days by -59.07% in comparison to the 20-day moving average, which settled at $4.21. In addition, Agilon Health Inc saw 52.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGL starting from McLoughlin Karen, who purchase 25,000 shares at the price of $2.20 back on Dec 13 ’24. After this action, McLoughlin Karen now owns 73,166 shares of Agilon Health Inc, valued at $55,085 using the latest closing price.
Battaglia Silvana, the Director of Agilon Health Inc, purchase 25,062 shares at $2.01 during a trade that took place back on Dec 11 ’24, which means that Battaglia Silvana is holding 66,144 shares at $50,269 based on the most recent closing price.
Stock Fundamentals for AGL
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- -0.0 for the gross margin
The net margin for Agilon Health Inc stands at -0.04. The total capital return value is set at -0.5. Equity return is now at value -42.95, with -12.02 for asset returns.
Based on Agilon Health Inc (AGL), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -46.76.
Currently, EBITDA for the company is -218.19 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 0.17. The receivables turnover for the company is 5.96for trailing twelve months and the total asset turnover is 3.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.20.
Conclusion
In conclusion, Agilon Health Inc (AGL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
